NASDAQMaterialsSpecialty ChemicalsSnapshot 2026-07-09
Reading SOLS? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →QuarterlyIQ Insights · SOLS
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-07-11. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $61 the market pays 28× p/e — above the 18× p/e peer median but in line with its own 40× history. That premium reflects a durable franchise our peer-anchored $72 fair value understates; treat the 'expensive vs peers' read with medium confidence. Analysts target $48–$102. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $90.00 | — | — | Analyst | high |
| Peer P/E | 12M | $38.83 | 18.0 | 2.16 | TTM | high |
| PEG | 12M | $42.66 | 19.7 | 2.16 | TTM | high |
| Own P/E history | 12M | $87.03 | 40.3 | 2.16 | TTM | high |
| triangulated | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
$48.00 – $102.00 (median $90.00) · 9 analysts · as of 2026-07-09
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Cheaper than its own typical valuation.
| $39.43 |
| 18.0 |
| 2.19 |
| Triangulated |
| high |
| Peer P/E | 3Y | $59.05 | 18.0 | 3.29 | Analyst | medium |
| PEG | 3Y | $64.88 | 19.7 | 3.29 | Analyst | medium |
| Own P/E history | 3Y | $132.37 | 40.3 | 3.29 | Analyst | medium |
| Peer P/E | 5Y | $78.10 | 18.0 | 4.35 | Analyst | high |
| PEG | 5Y | $85.80 | 19.7 | 4.35 | Analyst | high |
| Own P/E history | 5Y | $175.05 | 40.3 | 4.35 | Analyst | high |
